Collectively, these data underscore the widespread occurrence of AS events in GC and suggest that ACTA2, AREG, BRCA1, DDX5, MSH6, and PARP1 could serve as potential biomarkers for GC prognosis and progression. This evidence concerns the gene PARP1 and gastric cancer.